Nasopharyngeal Cancer

Patients with nasopharyngeal carcinoma who received radiotherapy in the morning survived longer than those who underwent radiotherapy later in the day, according to study results.

Individuals with cannabis-related disorder exhibited increased risk for head and neck cancer, results of a retrospective cohort study showed.

Individuals who smoke tobacco using a waterpipe had a higher risk for death from multiple cancer types compared with those who never smoked, according to data from an ongoing cohort study published in JAMA Oncology.

The FDA approved toripalimab-tpzi for two indications as treatment for nasopharyngeal carcinoma, making it the first approved therapy for this malignancy.

The FDA granted fast track designation to two oncology therapies.

Patients with nasopharyngeal cancer who underwent COVID-19 vaccination had a better response to a combination of anti-PD-1 therapy and chemotherapy than their unvaccinated counterparts, according to a letter published in Annals of Oncology.

The addition of tislelizumab to chemotherapy conferred a clinically meaningful PFS benefit among patients with recurrent or metastatic nasopharyngeal cancer, according to updated results of the randomized phase 3 RATIONALE-309 study.

Incidence of nasopharyngeal cancer differed greatly among Asian American ethnic subgroups, with significantly higher risk among Chinese and Laotian individuals compared with white individuals, according to study results.